Form 4: Cormorant Asset Management Reduces Stake in OnKure Therapeutics

Cormorant Asset Management reports a transaction involving the disposal of shares in OnKure Therapeutics, while maintaining significant beneficial ownership.

Summary

• On May 12, 2025, Cormorant Asset Management, LP disposed of 24,300 shares of OnKure Therapeutics, Inc. Class A Common Stock at a price of $1.985 per share.
• Following the transaction, Cormorant Asset Management's beneficial ownership in OnKure Therapeutics stands at 1,813,439 shares.
• The shares are indirectly held through various funds managed by Cormorant Asset Management, including Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare Fund IV, LP, and Cormorant Private Healthcare Fund V, LP.
• Bihua Chen, as managing member of the general partners of these funds and the general partner of Cormorant Asset Management, LP, is also a reporting person.
• The reporting persons disclaim beneficial ownership of the shares except to the extent of their pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral sentiment as it is a standard disclosure of a transaction. The reduction in stake could be seen as slightly negative, but without further context, it's difficult to assess the overall impact.

Negatives

• Cormorant Asset Management reduced its stake in OnKure Therapeutics by disposing of 24,300 shares.

Management Comments

• Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders or major shareholders of a publicly traded company buy or sell the company's stock; this filing indicates changes in Cormorant Asset Management's ownership position in OnKure Therapeutics.

Stakeholder Impact

• Shareholders may react to the change in ownership reported by a major shareholder like Cormorant Asset Management.

Key Dates

Keywords

OnKure Therapeutics, Cormorant Asset Management, Class A Common Stock, Beneficial Ownership, Form 4, Securities Exchange Act, Bihua Chen, Transaction